Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Myriad Genetics Is Tumbling Today

By Cory Renauer – Jun 11, 2020 at 1:22PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Coronavirus testing is up, but the pandemic has hammered demand for Myriad's hereditary cancer tests.

What happened

Shares of Myriad Genetics (MYGN -2.35%), a molecular diagnostics company, are falling in response to a negative analyst note that suggests demand for elective testing won't return as quickly as investors want it to. The stock has fallen 17.4% as of 1:47 p.m. EDT on Thursday.

So what 

During the first three months of 2020, testing revenue fell 25% compared to the previous year, and Jonathan Palmer from Bloomberg Intelligence thinks Myriad Genetics shareholders should brace for more disappointment. Myriad leans on its flagship hereditary cancer business for 52% of total revenue and Palmer estimates test volumes could drop by 70% to 75% during the present quarter.

Person drawing a downward sloping chart.

Image source: Getty Images.

Myriad has been expanding its suite of diagnostic tools beyond testing for hereditary signs of increased cancer risk, but these services were struggling to get off the ground before the COVID-19 pandemic began pressuring demand for elective testing. During the nine months ended March 31, 2020, sales of the company's GeneSight brand antidepressant test fell 21% year over year and prenatal testing fell 25% over the same time frame.

Now what

Bargain shoppers probably don't want to try catching this falling knife. Myriad finished March with $182 million in cash and securities after its operations lost $133.7 million during the first three months of the year. 

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Myriad Genetics, Inc. Stock Quote
Myriad Genetics, Inc.
MYGN
$18.69 (-2.35%) $0.45

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
329%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.